VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...

Dynavax is giving up work on its combination vaccine for tetanus, diphtheria and acellular pertussis (Tdap) after mulling phase 1 data for the shot. | Dynavax is giving up on its combination vaccine ...

Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...

Comprehensive coverage of the hexavalent vaccine can protect again whooping cough and polio writes Esther Nakkazi.

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s (Euronext: SAN) Flublok (Influenza Vaccine) to include data from a new safety study involving ...

About Sanofi SA (ADR) and Novartis AG (ADR ... meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides ...

IGRA presents more significant advantages than tuberculin skin tests because these are more accurate and sensitive, ...

In a dramatic turn of events that makes for some great storytelling, Cidara's novel drug-Fc conjugate, once locked up in a ...

Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined ... Lantus vial or cartridge (Sanofi-Aventis) 28 days ...